| Overview |
| bs-2185R |
| TDRD9/HIG1 Polyclonal Antibody |
| ELISA, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Cow, Horse |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human TDRD9/HIG1 |
| 801-900/1382 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 122402 |
| Cytoplasm, Nucleus |
| C14orf75; chromosome 14 open reading frame 75; HIG 1; Hypoxia inducible HIG 1; MGC135025; Putative ATP dependent RNA helicase TDRD9; Putative ATP-dependent RNA helicase TDRD9; TDRD 9; Tdrd9; TDRD9_HUMAN ; Tudor domain containing 9; Tudor domain containing protein 9; Tudor domain-containing protein 9. |
| Probable ATP-binding RNA helicase which plays a central role during spermatogenesis by repressing transposable elements and prevent their mobilization, which is essential for the germline integrity. Acts via the piRNA metabolic process, which mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and govern the methylation and subsequent repression of transposons. Its association with PIWIL4 and the piP-bodies suggests a participation in the secondary piRNAs metabolic process. |
| Application Dilution |
| ELISA |
1:500-1000 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz